PLDT Inc. (PHI): Hedge Fund Sentiment Unchanged
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge f...
Insider Monkey · 2d ago
NeoGenomics completes Inivata acquisition
NeoGenomics (NEO) has completed the previously announced acquisition of commercial stage liquid biopsy platform company Inivata.Inivata will become a liquid biopsy focused division alongside NeoGenomics' growing clinical, pharma and informatics divisions, ...
Seekingalpha · 2d ago
NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)? · 3d ago
Moving Average Crossover Alert: NeoGenomics (NEO) · 06/08 12:01
Goldman Sachs picks the health tech stocks set for a post-pandemic boom
Testing for the coronavirus is here to stay and the high-margin health diagnostics industry is set for a boost, Goldman said. · 06/08 05:08
Insider Makes Significant Stock Sells in NeoGenomics (NEO) Shares
MT Newswires · 06/07 22:36
Insider Trends: NeoGenomics Insider Extends 90-Day Selling Trend
MT Newswires · 06/04 20:06
Goldman Sachs Starts NeoGenomics at Buy With $55 Price Target
MT Newswires · 06/03 06:17
Abaxx Technologies Inc. Announces Additions to Executive Management and Market Structure Advisory Leads
Abaxx Technologies Inc., (ABXX:NEO)(ABXXF:OTCQX) ("Abaxx" or the "Company"), a financial software (fintech) company, majority shareholder of Abaxx Singapore Pte. Ltd., the Abaxx Commodity Exchange (ACX), and producer of the SmarterMarkets(TM) Podcast, anno...
GlobeNewswire · 06/02 13:27
NeoGenomics To Participate Virtually In Multiple Upcoming Institutional Investor Conferences
FT MYERS, FL / ACCESSWIRE / May 27, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating virtually ...
ACCESSWIRE · 05/27 20:05
Truist Securities Adjusts NeoGenomics' Price Target to $54 From $65, Maintains Buy Rating
MT Newswires · 05/25 10:00
NeoGenomics (NASDAQ:NEO) Shareholders Have Enjoyed A Whopping 335% Share Price Gain
It hasn't been the best quarter for NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders, since the share price has fallen 28...
Simply Wall St. · 05/25 08:44
First Light Asset Management, LLC Buys Cutera Inc, Aldeyra Therapeutics Inc, Sutro Biopharma ...
GuruFocus News · 05/18 18:38
Artisan Remains Optimistic on the Longer-Term Profit Cycle Potential of NeoGenomics (NEO)
Artisan Partners, a high value-added investment management firm, published its ‘Artisan Small Cap Fund’ first quarter 2021 investor letter – a copy of which can be downloaded here. A return of -5.02% was recorded by its Investor Class: ARTSX, -4.99% by its...
Insider Monkey · 05/18 16:33
Earnings Scheduled For May 13, 2021
  Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Benzinga · 05/13 08:15
Biocept Reports First Quarter 2021 Financial Results
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2021 and provides a business update.
BusinessWire · 05/12 20:05 featured highlights include: HealthEquity, NeoGenomics, Howard Hughes Corp and StoneCo · 05/12 13:02
Don't Let These 4 Toxic Stocks Erode Your Wealth · 05/11 13:11
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.